Breaking News Instant updates and real-time market news.

DXCM

Dexcom

$56.05

-0.23 (-0.41%)

, MDT

Medtronic

$85.81

-0.8734 (-1.01%)

15:25
01/22/18
01/22
15:25
01/22/18
15:25

Piper Jaffray medical technology analyst holds analyst/industry conference call

Medical Technology Analyst McKim, along with Dr. Ponder of Sugar Surfing, discuss Continuous Glucose Monitoring (CGM) systems, Libre vs. DXCM vs MDT, as well as the pump market landscape, MDT, PODD and TNDM on an Analyst/Industry conference call to be held on January 22 at 4:30 pm.

DXCM

Dexcom

$56.05

-0.23 (-0.41%)

MDT

Medtronic

$85.81

-0.8734 (-1.01%)

PODD

Insulet

$75.18

2.29 (3.14%)

TNDM

TNDM

ABT

Abbott

$59.39

0.075 (0.13%)

  • 22

    Jan

  • 24

    Jan

  • 26

    Feb

  • 27

    Feb

  • 01

    Mar

DXCM Dexcom
$56.05

-0.23 (-0.41%)

01/18/18
PIPR
01/18/18
NO CHANGE
Target $82
PIPR
Overweight
Insulet is a favored diabetes play on business momentum, says Piper Jaffray
Piper Jaffray analyst JP McKim says he hosted calls yesterday with two Certified Diabetes Educators from a "high volume center" and learned that they expect Continuous Glucose Monitoring - CGM - to become a "standard of care" in the Type 1 market, which can reach penetration of 85% vs 40% today. The analyst says the findings support his view that CGM is set for accelerating growth. Kim also notes that the impact on Medtronic (MDT) is improving, while the business momentum at Insulet (PODD) continues. The analyst rates Insulet as his top choice, followed by Dexcom (DXCM) and Tandem Diabetes Care (TNDM) in the space, given the headline risk around Libre coverage and insufficient evidence of accelerating pump additions for the latter names respectively. Kim keeps his Overweight rating and $82 price target on Insulet.
01/04/18
BARD
01/04/18
NO CHANGE
Target $58
BARD
Neutral
Risk to Dexcom estimates may be less than feared, says Baird
Baird analyst Jeff Johnson says his channel checks indicate Abbott's (ABT) Libre will be reimbursed by Centers for Medicare & Medicaid Services using the same codes as Dexcom's (DXCM) G5, meaning at the same monthly price of $250 per patient. The analyst has long believed superior technology, or G5 over Libre, will win out at price parity. As such, he believes today's news may not be create as much near-term risk to Dexcom numbers as investors believe. The analyst, however, keeps a Neutral rating on Dexcom shares, despite today's 11% selloff. He believes longer-term CMS and commercial payer questions remain.
01/05/18
LEER
01/05/18
NO CHANGE
Target $75
LEER
Outperform
Dexcom pricing risk less bad than feared, says Leerink
Leerink analyst Danielle Antalffy says her conversation with a specialist reinforced her view that Dexcom (DXCM) will continue to warrant at least some price premium to Abbott's (ABT) Libre given its alert and alarm capabilities and what is presumably better outcomes for patients. The analyst continues to recommend buying Dexcom on yesterday's, particularly for investors with at least a six month time horizon. She reiterates an Outperform rating on the shares with a $75 price target. Antalffy sees the company's pricing risk as less bad than feared following yesterday's news of Abbott securing Medicaid approval sooner than expected for its Freestyle Libre.
01/05/18
WBLR
01/05/18
NO CHANGE
WBLR
Outperform
William Blair sees Dexcom remaining 'product-of-choice' in glucose monitoring
William Blair analyst Margaret Kaczor believes Dexcom (DXCM) will remain the "product-of-choice" in glucose monitoring after Abbott (ABT) received Medicare approval for its Freestyle Libre Flash. While the approval comes six to nine months earlier than anticipated, Abbott's broader presence will likely expand patient awareness, Kaczor tells investors in a research note. She believes Dexcom is well positioned given its alerts and alarms in this "more vulnerable patient population." The analyst keeps an Outperform rating on the shares following yesterday's selloff.
MDT Medtronic
$85.81

-0.8734 (-1.01%)

01/04/18
01/04/18
DOWNGRADE

Underperform
Dexcom to Underperform at Northland
As previously reported, Northland analyst Suraj Kalia downgraded Dexcom (DXCM) to Underperform from Market Perform after Abbott (ABT) announced Medicare coverage for its Libre FGM. The analyst believes it undercuts Dexcom's competitive advantages, and contends that there is additional headline risk vis-a-vis Medtronic' (MDT) Guardian Connect CGM approval in the pipeline. Further, Kalia believes Dexcom's stock is bound to be under pressure over the next 12-18 months.
01/03/18
EVER
01/03/18
INITIATION
Target $92.5
EVER
Outperform
Medtronic initiated with an Outperform at Evercore ISI
Evercore ISI analyst Vijay Kumar started Medtronic with an Outperform rating and $92.50 price target. The analyst has confidence in the company's revenue growth accelerating in the second half of 2018. He finds the stock "compelling" at current share levels.
01/02/18
BOFA
01/02/18
UPGRADE
BOFA
Buy
Medtronic upgraded to Buy at BofA/Merrill
As previously reported, BofA/Merrill upgraded Medtronic to Buy from Neutral and increased its price target to $94 from $90. Analyst Bob Hopkins believes Medtronic is on the "verge" of delivering more consistent growth driven by its pipeline and manufacturing footprint reduction, which should drive multiple expansion.
PODD Insulet
$75.18

2.29 (3.14%)

01/08/18
LEER
01/08/18
NO CHANGE
LEER
Outperform
Meaningful upside likely for Insulet in 2019, says Leerink
Leerink analyst Danielle Antalffy notes that Insulet announced that CMS has granted coverage of its OmniPod. While the analyst says this coverage decision was well expected, she believes it positions the company for potential upside to his 2018 sales estimates and sees meaningful upside likely in 2019 and beyond. Antalffy reiterates an Outperform rating on the shares.
01/08/18
RAJA
01/08/18
UPGRADE
RAJA
Outperform
Insulet upgraded to Outperform from Market Perform at Raymond James
01/08/18
01/08/18
UPGRADE
Target $80

Outperform
Insulet upgraded to Outperform on upcoming tailwinds at Raymond James
As previously reported, Raymond James upgraded Insulet (PODD) to Outperform from Market Perform and established an $80 price target. Analyst Jayson Bedford has increased confidence in estimates from several tailwinds that include a share gain opportunity in US insulin pumps following Johnson & Johnson's (JNJ) exit from the market in September, incremental Medicare reimbursement for OmniPod, potential growth as it enters new countries, and the expected launch of its new Bluetooth-enabled OmniPod and PDM, its first new product in five years.
TNDM TNDM

10/05/17
COWN
10/05/17
NO CHANGE
COWN
J&J exit 'great opportunity' for Insulet and Tandem, says Cowen
Cowen analyst Doug Schenkel says close to 10% of the U.S. insulin pump market is up for grabs over the next two years after Johnson & Johnson's (JNJ) Animas announced it is exiting the pump business. Medtronic (MDT) is likely to get the majority of patients initially, but the news is a "great opportunity" for Insulet (PODD) and Tandem Diabetes Care (TNDM), Schenkel tells investors in a research note. The analyst sees risk for Dexcom (DXCM), but believes the vast majority of its users will remain, regardless of pump choice.
10/10/17
WEDB
10/10/17
NO CHANGE
Target $17
WEDB
Outperform
Tandem Diabetes price target lowered to $17 from $50 at Wedbush
Wedbush analyst Tao Levy lowered his price target for Tandem Diabetes to $17 from $50 to reflect the risk of further dilution as it seeks to improve its cash position. He reiterates an Outperform rating on the shares.
11/21/17
PIPR
11/21/17
NO CHANGE
PIPR
Piper says selection for Lilly 'diabetes ecosystem' a clear positive for Dexcom
Piper Jaffray analyst Matt O'Brien said it was news to him that Eli Lilly (LLY) is developing a diabetes pump and smart pen as part of its "diabetes ecosystem" plans. The company's selection of Dexcom's (DXCM) CGM as part of their integrated system is a clear positive for Dexcom, while Lilly's launch of an integrated system in the U.S. market is a modest negative for Insulet (PODD) and Tandem Diabetes (TNDM) given it will create a competitive headwind starting in 2021, added O'Brien.
ABT Abbott
$59.39

0.075 (0.13%)

01/22/18
BTIG
01/22/18
DOWNGRADE
BTIG
Neutral
Abbott downgraded to Neutral at BTIG on valuation
As noted earlier, BTIG analyst Sean Lavin downgraded Abbott to Neutral from Buy. Lavin says the stock price has run up about 50% over the past year, and "a lot of the positives are priced in". The analyst further contends that while there may be some potential benefit from the U.S. tax reform, he does not see another 15% of upside over the next 12 months as shares now trade at a valuation above the company's peers.
01/22/18
BTIG
01/22/18
DOWNGRADE
BTIG
Neutral
Abbott downgraded to Neutral from Buy at BTIG

TODAY'S FREE FLY STORIES

SLCA

U.S. Silica

$30.75

-0.8 (-2.54%)

06:08
02/21/18
02/21
06:08
02/21/18
06:08
Earnings
U.S. Silica reports Q4 EPS 89c, consensus 54c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 30

    May

DDAIF

Daimler AG

$86.88

-3.41 (-3.78%)

06:08
02/21/18
02/21
06:08
02/21/18
06:08
Periodicals
Daimler aims to begin serial production of eActros truck in 2021, Reuters says »

Daimler plans to commence…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGI

Alamos Gold

$5.37

-0.25 (-4.45%)

06:07
02/21/18
02/21
06:07
02/21/18
06:07
Hot Stocks
Alamos Gold reports 2017 year-end mineral reserves up 28% »

Alamos Gold reported its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

INOV

Inovalon

06:06
02/21/18
02/21
06:06
02/21/18
06:06
Earnings
Inovalon sees 2018 EPS 31c-35c, consensus 36c »

Sees 2018 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

UTHR

United Therapeutics

$134.96

0.03 (0.02%)

06:05
02/21/18
02/21
06:05
02/21/18
06:05
Earnings
United Therapeutics reports Q4 EPS $3.89, consensus $3.89 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

CLNE

Clean Energy

$1.43

-0.03 (-2.05%)

06:05
02/21/18
02/21
06:05
02/21/18
06:05
Hot Stocks
Clean Energy, HTA announce a new partnership »

The Harbor Trucking…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Mar

JELD

Jeld-Wen

$37.64

0.09 (0.24%)

06:03
02/21/18
02/21
06:03
02/21/18
06:03
Earnings
Jeld-Wen sees 2018 revenue growth 8.0%-11.0%, consensus $4.09B »

Sees 2018 adjusted EBITDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

  • 28

    Mar

T

AT&T

$36.77

-0.37 (-1.00%)

, CHTR

Charter

$358.77

-6.89 (-1.88%)

06:03
02/21/18
02/21
06:03
02/21/18
06:03
Periodicals
FCC expected to publish reversal of net neutrality rules, Reuters reports »

The FCC is expected to…

T

AT&T

$36.77

-0.37 (-1.00%)

CHTR

Charter

$358.77

-6.89 (-1.88%)

CMCSA

Comcast

$39.47

-0.32 (-0.80%)

CMCSK

Comcast

VZ

Verizon

$48.92

-1.23 (-2.45%)

NFLX

Netflix

$278.55

0.03 (0.01%)

GOOG

Alphabet

$1,102.46

7.66 (0.70%)

GOOGL

Alphabet Class A

$1,103.59

8.09 (0.74%)

AMZN

Amazon.com

$1,468.35

19.66 (1.36%)

FB

Facebook

$176.01

-1.35 (-0.76%)

TWTR

Twitter

$32.84

-0.22 (-0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 26

    Feb

  • 26

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

  • 28

    Feb

  • 01

    Mar

  • 01

    Mar

  • 05

    Mar

  • 06

    Mar

  • 07

    Mar

  • 18

    Mar

  • 20

    Mar

CVEO

Civeo

$3.34

-0.03 (-0.89%)

06:03
02/21/18
02/21
06:03
02/21/18
06:03
Hot Stocks
Civeo receives approval for pending acquisition of Noralta Lodge »

Civeo announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

PTEN

Patterson-UTI

$17.96

-0.13 (-0.72%)

06:03
02/21/18
02/21
06:03
02/21/18
06:03
Hot Stocks
Patterson-UTI acquires Superior QC »

Patterson-UTI announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JELD

Jeld-Wen

$37.64

0.09 (0.24%)

06:01
02/21/18
02/21
06:01
02/21/18
06:01
Earnings
Jeld-Wen reports Q4 adjusted EPS 26c, consensus 42c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

  • 28

    Mar

AMZN

Amazon.com

$1,468.35

19.66 (1.36%)

06:00
02/21/18
02/21
06:00
02/21/18
06:00
Periodicals
Amazon tried to buy smart lock maker August Home for $100M, The Information says »

Amazon tried to buy smart…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 18

    Mar

VRX

Valeant

$18.58

-0.3 (-1.59%)

, TEVA

Teva

$19.98

-0.92 (-4.40%)

05:55
02/21/18
02/21
05:55
02/21/18
05:55
Recommendations
Valeant, Teva analyst commentary  »

Deutsche sees rifamycin…

VRX

Valeant

$18.58

-0.3 (-1.59%)

TEVA

Teva

$19.98

-0.92 (-4.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 13

    May

  • 18

    Jun

  • 27

    Aug

BT

BT Group

$16.24

0.05 (0.31%)

05:49
02/21/18
02/21
05:49
02/21/18
05:49
Upgrade
BT Group rating change  »

BT Group upgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

VLVLY

Volvo AB

$19.42

-0.03 (-0.15%)

05:47
02/21/18
02/21
05:47
02/21/18
05:47
Initiation
Volvo AB initiated  »

Volvo AB initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSE

Trinseo

$78.85

-2.2 (-2.71%)

05:44
02/21/18
02/21
05:44
02/21/18
05:44
Recommendations
Trinseo analyst commentary  »

Trinseo valuation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NBL

Noble Energy

$29.12

2.84 (10.81%)

05:42
02/21/18
02/21
05:42
02/21/18
05:42
Recommendations
Noble Energy analyst commentary  »

Noble Energy price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

05:40
02/21/18
02/21
05:40
02/21/18
05:40
General news
FX Action: USD-CAD clocked a 12-day high »

FX Action: USD-CAD…

PTLA

Portola Pharmaceuticals

$48.22

0.53 (1.11%)

05:34
02/21/18
02/21
05:34
02/21/18
05:34
Recommendations
Portola Pharmaceuticals analyst commentary  »

Portola selloff overdone…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 04

    May

MRK

Merck

$54.98

-1.31 (-2.33%)

05:34
02/21/18
02/21
05:34
02/21/18
05:34
Hot Stocks
Merck to acquire Viralytics for about $394M »

Merc and Viralytics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Mar

  • 25

    Mar

  • 03

    Apr

  • 04

    Apr

  • 23

    Apr

  • 23

    Apr

  • 23

    Oct

BHVN

Biohaven Pharmaceutical

$29.58

-0.03 (-0.10%)

, CTLT

Catalent

$42.48

-0.89 (-2.05%)

05:30
02/21/18
02/21
05:30
02/21/18
05:30
Hot Stocks
Biohaven Pharmaceutical announces exclusive license with Catalent »

Biohaven Pharmaceutical…

BHVN

Biohaven Pharmaceutical

$29.58

-0.03 (-0.10%)

CTLT

Catalent

$42.48

-0.89 (-2.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 04

    Mar

  • 03

    May

BHP

BHP Billiton

$46.55

-2.14 (-4.40%)

, RIO

Rio Tinto

$56.27

-1.55 (-2.68%)

05:30
02/21/18
02/21
05:30
02/21/18
05:30
Downgrade
BHP Billiton, Rio Tinto rating change  »

BHP Billiton downgraded…

BHP

BHP Billiton

$46.55

-2.14 (-4.40%)

RIO

Rio Tinto

$56.27

-1.55 (-2.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

VJET

voxeljet

$4.00

-0.534 (-11.79%)

05:27
02/21/18
02/21
05:27
02/21/18
05:27
Recommendations
voxeljet analyst commentary  »

voxeljet making progress…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLDP

Ballard Power

$3.29

-0.08 (-2.37%)

05:27
02/21/18
02/21
05:27
02/21/18
05:27
Hot Stocks
Ballard Power receives follow-on purchase order from Nisshinbo Holdings »

Ballard Power Systems…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 01

    Mar

  • 11

    Mar

  • 29

    Mar

  • 23

    May

NFLX

Netflix

$278.55

0.03 (0.01%)

05:24
02/21/18
02/21
05:24
02/21/18
05:24
Recommendations
Netflix analyst commentary  »

Netflix price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 26

    Feb

  • 20

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.